Fredun Pharmaceuticals Q1 Results: Net profit up 94.63% YoY to ₹13.17 crore
Fredun Pharmaceuticals reported Q1 FY27 standalone total income of ₹228.25 crore, up 90.44% YoY, with net profit rising 94.63% YoY to ₹13.17 crore. EBITDA grew 92.90% YoY to ₹32.78 crore, with EBITDA margin expanding 18 bps to 14.36% and net profit margin improving 12 bps to 5.77%. Management guided for FY27 revenue of approximately ₹800 crore and outlined CapEx of ₹30 crore to ₹40 crore for the year, alongside 40% to 50% growth targets in pet care and 25% to 35% growth in the GX segment.
*this image is generated using AI for illustrative purposes only.
Fredun Pharmaceuticals Limited delivered a strong set of numbers for Q1 FY27, with standalone total income rising 90.44% YoY to ₹228.25 crore. Net profit grew 94.63% YoY to ₹13.17 crore, while EBITDA expanded 92.90% YoY to ₹32.78 crore. The results were discussed at the company's earnings conference call held on August 13, 2026, moderated by Kirin Advisors, with Managing Director Fredun Medhora addressing investor questions.
Q1 FY27 financial highlights
The company's operating and profitability metrics showed broad-based improvement across the quarter. EBITDA margin came in at 14.36%, expanding 18 bps YoY, while net profit margin improved to 5.77%, up 12 bps YoY.
| Metric | Q1 FY27 | YoY change |
|---|---|---|
| Total income | ₹228.25 crore | +90.44% |
| EBITDA | ₹32.78 crore | +92.90% |
| EBITDA margin | 14.36% | +18 bps |
| Net profit | ₹13.17 crore | +94.63% |
| Net profit margin | 5.77% | +12 bps |
Management noted that the quarter received a partial boost from orders booked in Q4 of the prior year, when the company offered customers favourable pricing ahead of broader price increases. The first quarter has historically been the weakest among the four quarters due to the nature of order cycles, with dispatches typically picking up from late April.
Business segments and growth strategy
Management outlined growth across several business verticals during the call:
- Pharmaceutical distribution (GX): Fredun GX is now present across 19 states with a revenue base of approximately ₹100 crore to ₹110 crore. Management guided for 25% to 35% annual growth in this segment over the next five years, with a medium-term target of ₹110 crore to ₹130 crore.
- New age brands: Growing at approximately 35% to 45% YoY, with some brands at higher rates due to a lower base.
- Vintage business: Growing at approximately 15% to 20% YoY.
- Pet care: Currently generating approximately ₹40 crore to ₹45 crore in revenue. Management guided for 40% to 50% YoY growth over the next three to four years, supported by functional foods, diagnostics, grooming, therapeutics, and the planned launch of cat food by Q3 or Q4 of FY27. Functional food sales for FY27 are targeted at ₹18 crore to ₹24 crore.
- Wagr.in: The pet parenting e-commerce platform had a soft launch around June 15. Management indicated that beta testing and back-end development are expected to be completed within 60 to 65 days of the call date, with full campaigns and partnerships expected within approximately 90 days.
The company also highlighted its manufacturing expansion, noting the addition of approximately 43 manufacturing locations across its five plants in Palghar. Management stated a goal of becoming one of the largest single-location manufacturing units by end of December 2028 or early 2029.
Capital expenditure and working capital
On capital allocation, management guided for ₹30 crore to ₹40 crore in CapEx for the current financial year, with a similar outlay planned for the following year. Over a two-year horizon, the CapEx range was indicated at ₹35 crore to ₹45 crore per year, covering facility upgrades and compliance with cGMP protocols.
Working capital stood at approximately ₹170 crore to ₹175 crore, against a run rate of approximately ₹850 crore. Management described this as appropriate for the company's scale, noting that approximately 50% of working capital is held as cash. Inventory days are being rationalised, with a near-term target of around 135 to 140 days and a medium-term range of 110 to 125 days. Management noted inventory days have fallen approximately 50% over the last two years.
Interest costs and credit profile
Interest costs declined on a QoQ basis despite significant YoY revenue growth. Management attributed this to improved cash flows, reduced utilisation of credit limits, and a credit rating upgrade from BBB to BBB+. The company indicated that interest spending as a proportion of topline has reduced materially.
Margin outlook and profitability trajectory
Management outlined segment-level gross margin ranges to contextualise the profitability path:
| Segment | Gross margin range |
|---|---|
| Pet care | 45% to 55% |
| Mobility | 40% to 50% |
| Nutrition | 35% to 50% |
| Dermaceutics | 70% to 75% |
Management noted that the blended improvement in margins is expected as higher-margin new age products constitute a larger share of revenue. A more pronounced uptick in profitability was indicated within the next 8 to 11 quarters, driven by completion of demographic reach and deeper penetration within existing channels. The company's revenue target for FY27 was stated at approximately ₹800 crore, with management noting that FY26 revenue of ₹635 crore exceeded the prior year's internal target of ₹570 crore.
Historical Stock Returns for Fredun Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
How will the upcoming launch of cat food in Q3/Q4 FY27 impact the pet care segment's projected 40-50% growth trajectory and overall revenue mix?
What specific operational strategies will Fredun Pharmaceuticals employ to further reduce inventory days from the current ~135-140 range to the medium-term target of 110-125 days?
Given the credit rating upgrade to BBB+, how might the company leverage improved access to capital to accelerate its goal of becoming one of the largest single-location manufacturing units by late 2028?
17
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
